Purchase this article with an account.
A. Labbe, E. Gabison, F. Baudouin, C. Tchokote, S. Menashi, C. Baudouin; Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression by Conjunctival Epithelial Cells in Patients Treated for Glaucoma. Invest. Ophthalmol. Vis. Sci. 2009;50(13):462.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the expression of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) by conjunctival epithelial cells in patients treated for glaucoma.
A total of 26 patients were included in this study. There were 18 glaucoma patients treated with topical antiglaucoma drugs for more than 6 months and 8 normal control subjects. Glaucoma patients were divided into two groups: 10 patients had 2 or more topical antiglaucoma treatments (multitreatment group) and 8 patients had only one treatment (monotherapy group). Impression cytology specimens were obtained from one eye of the patients and processed for flow cytometry analysis. Conjunctival epithelial cells were extracted and incubated with monoclonal antibodies against HLA-DR, EMMPRIN and their specific controls, to measure the expression of these two markers.
HLA-DR expression was raised significantly in the multitreatment group compared to the monotherapy group and the control group. HLA-DR expression in the monotherapy group was also significantly overexpressed compared to the control group. Similar findings were observed with a significant increase of EMMPRIN expression in the multitreatment group and the monotherapy group compared to the control group. There was a statistically significant correlation between EMMPRIN and HLA-DR expression by conjunctival epithelial cells both in glaucoma patients and normal subjects.
This study demonstrates the overexpression of EMMPRIN in the conjunctival epithelium of topically treated glaucoma patients. These results also suggest that inflammatory reactions are combined to matrix metalloproteinases modulation in the conjunctiva of patients treated for glaucoma. Further studies will assess the modulation and the role of EMMPRIN in ocular surface diseases associated to glaucoma topical treatment.
This PDF is available to Subscribers Only